SCHEMBL2179088

SCHEMBL2179088

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc5ccccc5c4)cc3)cc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 4/20 0.48
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
DGAT1 O75907 3/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
ITGA2 P17301 1/20 0.46
TMPRSS2 O15393 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
DEGS1 O15121 1/20 0.44
SDCBP O00560 1/20 0.44
SDC2 P34741 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718914 1.00 PLAU (0.48) PLAULMNATP53DGAT1RAB9A
SCHEMBL2180113 0.92 LMNA (0.48) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL13719015 0.92 LMNA (0.48) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL2178118 0.92 LMNA (0.48) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL2180687 0.91 PLAU (0.52) PLAULMNATP53DGAT1RAB9A
SCHEMBL2179321 0.91 LMNA (0.49) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL2179317 0.91 LMNA (0.49) LMNATP53ITGB3ITGA2BITGA2
SCHEMBL2181152 0.89 DGAT1 (0.42) PLAULMNATP53DGAT1RAB9A
SCHEMBL2176996 0.89 DGAT1 (0.42) PLAULMNATP53DGAT1RAB9A
SCHEMBL2179965 0.88 LMNA (0.51) LMNATP53ITGB3ITGA2BITGA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PLAU 1279/4885LMNA 2193/4885TP53 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.